How certain bacteria can enhance cancer treatment effectiveness
Official title: Defining mechanisms of how immune checkpoint inhibitor-associated bacteria modulate tumor immunity in cancer
Funded at University of Pittsburgh at Pittsburgh · NIH-11131468 · Data updated 2026-11-12
This study is looking at how certain good bacteria in your gut might help make cancer treatments work better for melanoma patients by boosting the immune system, especially the cells that fight tumors, and it hopes to find new ways to improve treatment for those who haven't had success with current options.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Pittsburgh at Pittsburgh NIH-funded |
| Lab location | 1 site (Pittsburgh, United States) |
| Project start | April 1, 2025 |
| Project end | March 31, 2030 |
| Funding year | 2025 |
| Award (this year) | $636,222 |
| NIH project number | 1R01CA293654-01A1 |
| Project ID | NIH-11131468 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are melanoma patients who are currently undergoing or considering immune checkpoint inhibitor therapy.
✕Less likely to help
Patients with cancers that do not respond to immune checkpoint inhibitors or those who are not eligible for such therapies may not benefit from this research.
What this research studies
This research investigates the role of specific bacteria in the gut microbiome that may improve the effectiveness of immune checkpoint inhibitors (ICIs) in cancer treatment, particularly for melanoma patients. The study aims to understand the mechanisms by which these bacteria enhance anti-tumor immunity, focusing on how they influence CD8+ T cells, which are crucial for fighting cancer. By exploring the interaction between dietary components and gut bacteria, the research seeks to identify new strategies to boost the immune response against tumors, potentially leading to better outcomes for patients resistant to current therapies.
Why it matters
Potential benefit: If successful, this research could lead to improved cancer treatments that enhance the effectiveness of existing therapies for patients with melanoma and potentially other cancers.
How similar studies have gone: Previous research has shown promising results in enhancing cancer treatment through microbiome interactions, suggesting that this approach could lead to significant advancements in cancer therapy.
Where this research is happening
-
University of Pittsburgh at Pittsburgh
Pittsburgh, United States Active
Researchers
- Principal investigator: Meisel, Marlies — University of Pittsburgh at Pittsburgh
- Study coordinator: Meisel, Marlies
Related research
Other NIH-funded projects on the same topics.
-
Autoimmune diabetes linked to cancer immunotherapy: discovering causes and biomarkers
This grant explores why some people on cancer immunotherapy develop autoimmune diabetes and aims to find biomarkers to predict and prevent it.
-
ctDNA biomarker to guide safety of cancer immunotherapy in inflammatory arthritis
A patient-facing biomarker study using a blood test to detect tumor DNA in people with cancer who develop inflammatory arthritis from immunotherapy, to help doctors pick safer treatment choices.
-
Cross-species study of immune responses to cancer immunotherapy in dogs and humans with invasive bladder cancer
A study using dogs with naturally occurring invasive bladder cancer to help improve immune checkpoint therapies for people with the same disease.
-
Characterizing the psychological symptoms in melanoma patients on immunotherapy
A long-term study follows adults with advanced skin cancer who are starting immune checkpoint therapy to understand the pattern of emotional and psychological symptoms they experience.
-
Immunologic and Antigenic Drivers of Immune Checkpoint Inhibitor–Associated Heart Inflammation
A doctor-scientist team is studying why cancer patients treated with immune checkpoint drugs sometimes develop dangerous heart inflammation and what immune targets cause it.
-
Pathway-guided treatment of colon toxicity from immune checkpoint inhibitors
A patient-focused look at a study that aims to understand and improve how immune checkpoint inhibitor therapy causes colon inflammation and how to treat it more effectively.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.